Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Betta Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Operating Revenue	3,009	2,827	2,417	2,342	2,206	1,824
Other Revenue	64.95	64.95	39.41	34.18	40.05	46.19
Revenue	3,074	2,892	2,456	2,377	2,246	1,870
Revenue Growth (YoY)	15.54%	17.74%	3.35%	5.82%	20.08%	20.36%
Cost of Revenue	581.78	538.52	404.48	268.69	174.44	138.9
Gross Profit	2,492	2,353	2,052	2,108	2,071	1,731
Selling, General & Admin	1,431	1,363	1,116	1,234	1,141	946.77
Research & Development	462.44	501.9	640.14	699.9	565.95	362.85
Other Operating Expenses	36.36	18.19	10.62	-34.51	15.24	6.99
Operating Expenses	1,928	1,876	1,772	1,901	1,723	1,317
Operating Income	564.38	476.96	279.88	206.96	348.77	414.79
Interest Expense	-56.13	-45.49	-54.95	-195.8	-15.78	-39.86
Interest & Investment Income	5.75	6.78	10.23	10.88	33.35	298.46
Currency Exchange Gain (Loss)	4.14	4.14	6.72	9.55	-3.63	-8.42
Other Non Operating Income (Expenses)	0.47	-1.45	-4.96	-9	-0.84	2.03
EBT Excluding Unusual Items	517.59	440.94	236.92	22.59	361.88	666.99
Gain (Loss) on Sale of Investments	-117.57	-40.97	-13.67	-20.62	1.01	-12.42
Gain (Loss) on Sale of Assets	1.24	-0.59	-0.01	88.61	0.07	-1.7
Asset Writedown	-28.05	-28.05	-1.07	-3.01	-0.03	-
Other Unusual Items	36.87	22.83	99.9	-	27.01	13.79
Pretax Income	410.08	394.16	322.07	87.57	389.93	666.66
Income Tax Expense	21.43	7.18	-11.54	-37.19	10.37	65.58
Earnings From Continuing Operations	388.65	386.98	333.62	124.76	379.56	601.09
Minority Interest in Earnings	15.87	15.59	14.42	20.66	3.51	5.27
Net Income	404.52	402.57	348.03	145.42	383.07	606.36
Net Income to Common	404.52	402.57	348.03	145.42	383.07	606.36
Net Income Growth	2.47%	15.67%	139.33%	-62.04%	-36.83%	162.70%
Shares Outstanding (Basic)	417	419	419	416	416	404
Shares Outstanding (Diluted)	417	419	419	416	416	407
Shares Change (YoY)	-0.47%	0.01%	0.72%	-0.02%	2.32%	1.09%
EPS (Basic)	0.97	0.96	0.83	0.35	0.92	1.50
EPS (Diluted)	0.97	0.96	0.83	0.35	0.92	1.49
EPS Growth	2.96%	15.66%	137.47%	-62.01%	-38.26%	161.40%
Free Cash Flow	254.79	83.58	-181.79	-703.8	-231.75	-39.81
Free Cash Flow Per Share	0.61	0.20	-0.43	-1.69	-0.56	-0.10
Dividend Per Share	0.200	0.200	0.170	0.070	0.250	0.310
Dividend Growth	17.65%	17.65%	142.86%	-72.00%	-19.36%	63.16%
Gross Margin	81.07%	81.38%	83.53%	88.69%	92.23%	92.57%
Operating Margin	18.36%	16.49%	11.39%	8.71%	15.53%	22.18%
Profit Margin	13.16%	13.92%	14.17%	6.12%	17.06%	32.42%
Free Cash Flow Margin	8.29%	2.89%	-7.40%	-29.61%	-10.32%	-2.13%
EBITDA	949.99	845.1	578.14	453.58	517.89	569.95
EBITDA Margin	30.91%	29.22%	23.54%	19.09%	23.06%	30.47%
D&A For EBITDA	385.61	368.14	298.26	246.62	169.12	155.16
EBIT	564.38	476.96	279.88	206.96	348.77	414.79
EBIT Margin	18.36%	16.49%	11.39%	8.71%	15.53%	22.18%
Effective Tax Rate	5.23%	1.82%	-	-	2.66%	9.84%
Revenue as Reported	3,074	2,892	2,456	2,377	2,246	1,870
Advertising Expenses	-	-	-	414.75	459.29	376.61

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.